Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab as Adjunctive Treatment in Major Depressive Disorder
NCT02473289Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of sirukumab in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: completed.
02
Drugs
sirukumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02473289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473289.